Long-term results of the RADIANCE-HTN TRIO trial: strengths and limitations
- PMID: 39379468
- DOI: 10.1038/s41440-024-01903-4
Long-term results of the RADIANCE-HTN TRIO trial: strengths and limitations
Erratum in
-
Correction: Long-term results of the RADIANCE-HTN TRIO trial: strengths and limitations.Hypertens Res. 2024 Dec;47(12):3499. doi: 10.1038/s41440-024-01947-6. Hypertens Res. 2024. PMID: 39379470 No abstract available.
Keywords: Hypertension guidelines; Renal denervation; Resistant hypertension.
Comment on
-
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.Hypertens Res. 2024 Dec;47(12):3467-3472. doi: 10.1038/s41440-024-01854-w. Epub 2024 Sep 27. Hypertens Res. 2024. PMID: 39333663 Free PMC article. Clinical Trial.
References
-
- Bloch MJ, Kirtane AJ, Azizi M, Mafhoud F, Basile J, Daemen J, et al. 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertens Res. 2024;47. https://doi.org/10.1038/s41440-024-01854-w
-
- Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. Authors/Task Force Members. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41:1874–2071. - DOI - PubMed
-
- Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777–83. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources